Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antibody-conjugated doxorubicin liposomal - NanoSmart/NanoValent

Next Previous
Drug Profile

Antibody-conjugated doxorubicin liposomal - NanoSmart/NanoValent

Alternative Names: ANA-conjugated doxorubicin liposomal - NanoSmart/NanoValent; Anti-nuclear antibody-conjugated doxorubicin liposomal - NanoSmart/NanoValent; Doxorubicin liposomal - NanoSmart/NanoValent

Latest Information Update: 28 Dec 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NanoSmart Pharmaceuticals; NanoValent Pharmaceuticals
  • Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Immunoconjugates; Small molecules
  • Mechanism of Action CD antigen inhibitors; DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Ewing's sarcoma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 28 Dec 2019 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA
  • 28 Dec 2019 No recent reports of development identified for preclinical development in Ewing's Sarcoma in USA
  • 28 Dec 2019 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top